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Background: Demand for dialysis treatment exceeds its supply within the Veterans Health Administration (VA),
requiring VA to outsource dialysis care by purchasing private sector dialysis for veterans on a fee-for-service basis. It
is unclear whether outcomes are similar for veterans receiving dialysis from VA versus non-VA providers. We
assessed the extent of chronic dialysis treatment utilization and differences in all-cause hospitalizations and
mortality between veterans receiving dialysis from VA versus VA-outsourced providers.
Methods: We constructed a retrospective cohort of veterans in 2 VA regions who received chronic dialysis
treatment financed by VA between January 2007 and December 2008. From VA administrative data, we identified
veterans who received outpatient dialysis in (1) VA, (2) VA-outsourced settings, or (3) both (“dual”) settings. In
adjusted analyses, we used two-part and logistic regression to examine associations between dialysis setting and
all-cause hospitalization and mortality one-year from veterans’ baseline dialysis date.
Results: Of 1,388 veterans, 27% received dialysis exclusively in VA, 47% in VA-outsourced settings, and 25% in dual
settings. Overall, half (48%) were hospitalized and 12% died. In adjusted analysis, veterans in VA-outsourced settings
incurred fewer hospitalizations and shorter hospital stays than users of VA due to favorable selection. Dual-system
dialysis patients had lower one-year mortality than veterans receiving VA dialysis.
Conclusions: VA expenditures for “buying” outsourced dialysis are high and increasing relative to “making” dialysis
treatment within its own system. Outcomes comparisons inform future make-or-buy decisions and suggest the
need for VA to consider veterans’ access to care, long-term VA savings, and optimal patient outcomes in its
placement decisions for dialysis services.
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Approximately 35,000 veterans enrolled in the Veterans
Health Administration (VA) have end-stage renal disease
(ESRD), reflecting a higher prevalence in the VA population
than in the general US population (604 vs. 187 per 100,000)
[1,2] that is likely due to veterans’ older age and greater
disease prevalence of diabetes and hypertension. The
organization of chronic dialysis services for veterans with
ESRD is complex because many are eligible for dialysis care
through either the VA, the largest integrated healthcare* Correspondence: virginia.wang@duke.edu
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reproduction in any medium, provided the orsystem in the US, or the Medicare program.a VA finances
roughly 60% of ESRD dialysis services for these veterans
and Medicare finances approximately 30% of dialysis ser-
vices [3-5]. Veterans are likely to favor dialysis care through
VA because the VA’s integrated care system provides a con-
tinuum of care and patients’ out-of-pocket cost-sharing is
lower in VA than Medicare.b To serve its ESRD veterans
seeking dialysis care, the VA operates 74 hospital-based VA
dialysis units that provide acute (inpatient) and chronic
(outpatient) treatments. When the VA is not capable of
meeting all veterans’ demand for chronic outpatient dialysis
or providing timely geographic access to thrice weekly
dialysis care at VA medical centers (VAMCs), the VA out-
sources dialysis care by purchasing services from non-VA
providers in the private sector on a fee-for-service basis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wang et al. BMC Health Services Research 2013, 13:26 Page 2 of 9
http://www.biomedcentral.com/1472-6963/13/26Prior work has examined utilization and outcomes of
renal care in VA and Medicare systems [4,6], but less is
known about the VA’s own organization of in- and out-
of-network chronic dialysis treatment services. VA-
outsourced dialysis is a major contributor to increasing
ESRD costs for the VA. While overall outpatient dialysis
expenditures for VA dialysis increased 10% between
1993 and 2003, payments for VA-outsourced dialysis
grew 348% (from $13.5 M to $60.7 M) during the same
period [7]. More recently, national expenditures for VA-
outsourced care further increased to $432 M in 2011 [8].
Growth in VA dialysis spending is likely due to a com-
bination of growth in the number of veterans with ESRD
seeking VA coverage and increasing costs of dialysis
treatment by outsourced providers. Of particular con-
cern is the VA’s reliance on outsourcing dialysis services
because VA exerts little clinical oversight or accountabi-
lity for quality or outcomes of outsourced care furnished
by non-VA providers.
Research has generally found outcomes of VA care to be
as good or better than non-VA care [9]. The few studies
comparing VA and non-VA (e.g., Medicare, Medicaid) sys-
tems for ESRD patient care are more mixed: renal patients
obtaining care in VA receive earlier pre-dialysis nephro-
logy care [10] and have better vascular access [11,12], but
may have less access to kidney transplantation [13] than
care received in non-VA settings.
In this study, we compare one-year hospitalizations
and mortality of veterans with ESRD who receive dialysis
through VA in-house and outsourced settings because
no prior study has examined outcomes between these
two settings. We also examine patient differences by dia-
lysis setting to understand whether healthier or sicker
veterans are more likely to be seen in outsourced set-
tings. Compared to VA-outsourced care in the private
sector, the VA’s closed system of care allows veterans to
have multiple VA clinic visits that coincide with dialysis
treatment sessions (3 times per week), which provides
timely access to address critical health needs. Thus, we
hypothesized that veterans receiving dialysis exclusively
in VA settings had lower hospitalization and mortality
rates than patients receiving dialysis in VA-outsourced
providers in the private sector. Since dual use of VA and
non-VA care may disrupt continuity of care and worsen
health outcomes [14,15], we expected outcomes among
veterans obtaining dialysis in both VA and VA-outsourced
settings to be different than patients exclusively receiving
either VA or VA-outsourced dialysis.
It is important to understand if outcomes differ between
VA, VA-outsourced and dual system dialysis use, because
VA expenditures for “buying” outsourced dialysis are high
and increasing relative to “making” dialysis treatment
within its own system and outcomes comparisons may in-
form future make or buy decisions. Such understanding isalso important in other non-VA healthcare settings be-
cause make-buy planning decisions are a challenge cur-
rently faced by other large health systems and will grow as
new care delivery models (e.g., Accountable Care Organi-
zations) develop.Methods
Study design and population
We conducted a retrospective cohort study of veterans
with ESRD in two regional, Veterans Integrated Service
Networks (VISN) who received chronic outpatient dialysis
treatment financed by VA between January 1, 2007 and
December 31, 2008. To identify veterans with ESRD re-
ceiving chronic outpatient dialysis, our sampling strategy
was adapted from the US Renal Data System (national re-
pository of ESRD information) [16] for analysis using VA
administrative data. We identified 2,540 veterans who
received any dialysis services financed by VA either in VA
or outsourced through the VA Fee Basis Program between
January 2007 and December 2008 (Figure 1). We excluded
patients who died within the first 90 days of their first
treatment during the observation period (n=314) because
dialysis treatment and exposure to treatment setting
would be too limited to derive meaningful effects [1]. To
further limit our examination of chronic dialysis patients
receiving care in outpatient settings, we also excluded
veterans who received: 1) only acute dialysis (defined as
fewer than 15 dialysis treatments in a 60-day window) [16]
or chronic dialysis exclusively as inpatients (n=642); 2) any
home-based dialysis treatment (e.g., peritoneal dialysis,
which is rarely used in the general US population and less
so among the veteran population) (n=143); or 3) received
the majority of their outpatient dialysis treatments outside
the two study regions (n=53).Data and measurement
Our outcomes of interest were all-cause hospitalizations
and mortality. We used the VA Patient Treatment (PTF)
and Fee Basis (FB) files to identify hospitalizations and
lengths-of-stay. All-cause mortality was identified from
the VA Vital Status file. For all outcomes, we followed
each subject one year from their start date which is
defined as the first date of dialysis during the study
period (i.e., on or after January 1, 2007).
VA outpatient encounter and FB claims files were
used to determine each veteran’s start date and to iden-
tify veterans’ source of outpatient dialysis treatment
thereafter. Outpatient dialysis treatment setting was the
explanatory variable of interest, defined as either exclu-
sively VA; exclusively VA-outsourced dialysis, or dual
settings (defined as receiving at least one outpatient-
based dialysis treatment in VA and VA-outsourced
dialysis).
Note: To identify dialysis treatment utilization, VA clinic stop codes (601-611) were used to identify VA dialysis 
service use in VA encounter files and CPT procedure codes (90935, 90937, 90945, 90947, and 90999) were used to 
identify nonVA dialysis service use in the VA Fee Basis claims files.  
Veterans Seen in VA Receiving Dialysis 
(with ESRD Diagnosis)
N = 2,399
Exclusion: Death
Died w/in 90 days of first dialysis treatment 
(on or after Jan 1 2007)
N = 173
Veterans Seen in VA Receiving Dialysis
Surviving 90 days of first dialysis
N = 2,226
Veterans on Chronic Dialysis (with ESRD)
Surviving 90 days of first dialysis
N = 1,584
Exclusions: Acute dialysis or 
dialysis exclusively as inpatient
< 15 dialysis treatments w/in 60 days
N = 642
Veterans on Chronic Hemodialysis
Surviving 90 days of first dialysis 
In-center HD 
N = 1,441
Exclusions: other modalities
Any peritoneal or home dialysis
N = 143
Veterans with ESRD on 
Chronic Hemodialysis in VISNs A or B
N = 1,388
Exclusions: majority outpatient treatment 
outside VISNs A or B
N = 53
Figure 1 Cohort of chronic dialysis veterans. Note: To identify dialysis treatment utilization, VA clinic stop codes (601–611) were used to
identify VA dialysis service use in VA encounter files and CPT procedure codes (90935, 90937, 90945, 90947, and 90999) were used to identify
nonVA dialysis service use in the VA Fee Basis claims files.
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lowing VA convention [17], we assessed the most recently
reported race (e.g., White, non-White, or unknown) from
VA inpatient and outpatient encounter data. We obtained
date of birth and gender from the VAVital Status File, and
we determined veteran eligibility and copayment status
from the VA Enrollment file. Comorbidity burden for each
veteran in the year prior to baseline was assessed using
the Diagnostic Cost Group (DCG) risk score from the an-
nual VA DCG file, which is as predictive of veterans’ one-
year mortality and expenditures as other comorbidity
scores [18-20]. We used PTF and FB files to determine
whether veterans were hospitalized in the year prior to
baseline. We also determined each patient’s history of dia-
lysis use prior to each subject’s start date in four mutually
exclusive time periods: none (i.e., incident users), 6 months
of prior use, 1 year of prior use, and 2 years of prior use.
Distance to VA dialysis was defined as straight-line dis-
tance (in miles) between veterans’ residence zip code and
the nearest VA dialysis unit zip code centroid. Last, we
included a dichotomous indicator of VISN to control for
patients’ service region effects.Analysis
To examine whether healthier or sicker veterans are more
likely to be seen in outsourced settings, we compared
patient characteristics and unadjusted outcomes across
veterans in the three dialysis settings using Chi-square
tests for categorical variables and ANOVA tests for
continuous variables. We then compared adjusted one-
year outcomes using multivariable regression models. For
our hospitalization outcome, we conducted logistic regres-
sion to estimate the probability of hospitalization at one
year, and then conducted negative binomial regression to
examine total hospitalizations and cumulative inpatient
length-of-stay among the subset of veterans who were
hospitalized. One-year mortality was analyzed via logistic
regression because we were not able to observe patients’
disease start or first ever dialysis treatment for assessing
time-to-death. All models controlled for veterans’ age, sex,
race, marital status, copayment status, distance to nearest
VA dialysis unit, history of dialysis utilization, a dichoto-
mous indicator of prior hospitalization, comorbidity bur-
den measured by the DCG score, and veterans’ Integrated
Service Network of residence. To determine whether
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basis of hospitalization during the follow-up period, we
also conducted stratified analyses of mortality among
veterans who were hospitalized at least once in the year
after baseline and veterans who had no hospitalizations.
This study and requisite waivers of patient informed con-
sent for retrospective analysis of administrative data were
approved by the Institutional Review Board of the Durham
VA Medical Center.
Results
Descriptive statistics
The final analytic cohort included 1,388 veterans who
received chronic outpatient hemodialysis treatment
financed by VA (Figure 1): 381 (27%) received dialysis
exclusively in the VA, 659 (47%) exclusively received VA-
outsourced dialysis, and 348 (25%) were dual users
(Table 1). VA users were more likely to be non-White, un-
married, younger, had higher comorbidity burden, and
lived closer to the nearest VA dialysis unit than veterans
exclusively receiving outpatient dialysis in VA-outsourced
or in dual dialysis settings (all, p<0.01).
Hospitalization differences between VA, VA Fee dialysis
and dual users
Approximately half (48%) of the cohort was hospitalized
one year after veterans’ baseline dialysis visit (Table 1).
Veterans receiving dialysis exclusively in VAMCs were
more likely to be hospitalized, compared to dual and VA-
outsourced dialysis users (65%, 30%, and 63% respectively,
p<0.001). Among those with any hospitalization (n=665),
veterans receiving dialysis in VA settings incurred more
all-cause hospitalizations (2.6 vs. 2.1, p<0.01) than VA-
outsourced dialysis users. Veterans receiving dialysis in
VA had greater cumulative lengths-of-stay on average
(22.9) than those in VA-outsourced or dual settings
(mean= 22.4 vs. 16.6 days, respectively), though these
differences were not statistically significant (p=0.146).
Consistent with the unadjusted results, veterans who
received outpatient dialysis exclusively in VA-outsourced
settings were less likely to be hospitalized than VA dialysis
users (OR= 0.35, p<0.001, Table 2). Among the hospitalized
veterans in our cohort, patients receiving VA-outsourced
dialysis incurred fewer inpatient admissions (β= −0.16,
p<0.05) and had shorter total length-of-stay than patients
receiving VA dialysis (β= −0.37, p<0.05). Higher comorbi-
dity burden and hospitalization in the year prior to baseline
was positively associated with any hospitalization and the
number of hospitalizations (p<0.01).
Mortality differences between VA, VA Fee dialysis and
dual user
Unadjusted one-year mortality was greater among VA
users (15%) compared to VA-outsourced dialysis patients(13%) and dual system dialysis users (8%, p<0.05). Com-
pared with VA dialysis (Table 3), use of both systems for
outpatient dialysis was associated with lower mortality
one-year after Veterans’ baseline (OR=0.52, p<0.05).
In mortality analysis stratified by hospitalization to exa-
mine whether the association between dialysis setting and
mortality was moderated by hospitalization, we restricted
the explanatory variables to dialysis setting, age, comorbi-
dity burden, dialysis utilization and hospitalization prior
to baseline, and distance to nearest VA dialysis unit. We
found no statistically significant differences in mortality by
dialysis setting among veterans who were not hospitalized
(p=0.05-0.60, Table 3 columns 2–3). For those who were
hospitalized, dual users had lower one-year mortality than
VA-only dialysis patients (OR=0.42, p<0.01).
Discussion
In this study, veterans receiving outpatient chronic dialysis
services from VA-outsourced dialysis providers were less
likely to be hospitalized and had shorter lengths-of-stay
when hospitalized, compared to veterans receiving dialysis
exclusively in VA. These outcome differences are likely
due to favorable selection into VA-outsourced dialysis be-
cause VA-outsourced dialysis veterans were generally
healthier than those who either used VA services exclu-
sively or used both systems for dialysis care. Since our
adjusted results accounted for comorbidity burden, there
may be other explanations for our findings. For example,
it is likely that VA retains the sickest patients and triages
lower risk patients outsourced dialysis care. It is also
possible that higher hospitalization rates of VA dialysis
users may be attributed to unmeasured factors or factors
unrelated to ESRD or dialysis treatment. Alternatively,
VA-outsourced dialysis facilities in the private sector may
provide better care than VA, despite inducing greater care
fragmentation. This latter explanation contradicts findings
from Trivedi and colleagues’ [9] review which found out-
comes in most primary care contexts to be generally better
in VA than non-VA settings. Considering that chronic dia-
lysis patients require frequent, costly, and life-sustaining
treatment that places them at high risk of adverse events
(e.g., cardiac events, infection), further research on the
quality of VA and VA-outsourced dialysis-specific care is
needed.
There were no mortality differences between exclu-
sive use of dialysis services through the VA or VA-
outsourced dialysis settings. Dual dialysis users had
lower one-year mortality than VA dialysis users, which is
largely driven by the 48% of veterans who were hospita-
lized within one-year after baseline (OR=0.42, p<0.01).
Even though VA-only and dual-system dialysis patients
had similar baseline comorbidity burden, dual-system
dialysis users may have lower one-year mortality because
they were healthy enough to have their care outsourced
Table 1 VA chronic dialysis patient baseline characteristics, by outpatient dialysis setting
Overall (n=1,388) VA (n=381) Non-VA (n=659) Dual (n=348) p
Age 62.2 (11.3) 61.7 (11.5) 63.2 (11.4) 61.0 (11.0) .005
Male, % 98.6 99.0 98.6 98.3 .736
Race, % <.001
White 38.3 24.7 47.6 35.3 –
Non-White 59.0 74.0 47.5 64.4 –
Unknown 2.7 1.3 4.9 0.3 –
Marital status, % <.001
Married 47.0 38.1 53.1 45.4 –
Unmarried 50.9 61.2 43.7 53.4 –
Unknown 2.0 0.8 3.2 1.1 –
Copayment required, % 6.0 8.1 5.3 4.9 .110
Diagnostic Cost Group (DCG) score 5.1 (3.1) 5.7 (3.1) 4.5 (3.0) 5.7 (3.0) <.001
Arrhythmia, % 15.9 19.4 14.7 14.1 .078
Cancer, % 12.5 13.1 10.2 16.1 .023
Cerebrovascular disease, % 13.4 13.4 12.4 15.2 .467
Congestive heart failure, % 28.2 28.3 28.2 28.2 .998
Chronic pulmonary disease, % 16.9 15.2 17.8 17.2 .568
Diabetes, % 63.8 60.9 62.5 69.5 .033
Hypertension, % 87.2 85.3 85.0 93.4 <.001
Myocardial infarction, % 6.3 5.2 7.0 6.3 .544
Liver disease, % 6.0 6.0 5.0 7.8 .216
Peripheral vascular disease, % 20.7 27.3 17.0 20.7 <.001
History of dialysis prior to baseline, % .001
None 48.6 51.4 43.1 56.0 –
6 months 8.2 5.5 9.7 8.3 –
1 year 5.8 4.7 6.4 5.8 –
2 years 37.4 38.3 40.8 29.9 –
History of hospitalization 1-year prior to baseline, % 52.2 63.5 41.6 59.8 <.001
Home VA station has dialysis, % 66.2 100 35.7 87.1 <.001
Distance to home VA station, miles 35.5 (45.4) 12.4 (39.7) 46.2 (38.6) 40.5 (53.5) <.001
Distance to nearest VA dialysis, miles 58.6 (59.6) 12.1 (36.4) 91.2 (52.0) 48.0 (55.6) <.001
Region, % <.001
VISN A 73.7 51.2 83.5 79.9 –
VISN B 26.3 48.8 16.5 20.1 –
All-cause Hospitalization, % 47.9 65.1 30.2 62.6 <.001
Hospitalizations for all subjects, mean 1.2 (1.7) 1.7 (2.0) 0.6 (1.3) 1.6 (2.0) <.001
Hospitalizations for patients with any hospitalization3, mean 2.4 (1.8) 2.6 (1.9) 2.1 (1.5) 2.6 (1.9) .002
Total length of stay for all subjects, mean 10.0 (27.1) 14.9 (32.9) 5.0 (15.0) 14.0 (35.3) <.001
Total length of stay for patients with any hospitalization3, mean 20.9 (36.2) 22.9 (38.5) 16.6 (23.6) 22.4 (42.4) .146
All-cause Mortality, % 12.5 14.7 13.4 8.3 .022
1. Notes: 1. Mean (SD) reported, unless noted otherwise.
2. ANOVA and Chi-square tests for differences by user type.
3. Reported means and standard deviations among patients with any hospitalization (n= 655, 47.9%).
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of follow-up.
Interestingly, one-year mortality in this veteran cohort
was lower than that of the general ESRD population that
received dialysis care from Medicare [16]. These findingswere consistent with recently reported [4] one-year mor-
tality of veterans receiving chronic dialysis treatment in
VA and Medicare programs. The relatively low mortality
among veterans receiving VA-financed dialysis may reflect
favorable pre-dialysis care among VA and dual use
Table 2 Adjusted all-cause hospitalization 1-year after baseline
Any Hospitalization
(n=1,388)
Total Number of Hospitalizations
(n=665)3
Total Hospital Length of Stay
(n=665)3
OR β β
Dialysis setting: Non-VA (ref: VA) .35*** (.24, .51) –.16* (.08) –.37* (.15)
Dual .99 (.70, 1.40) .01 (.07) –.05 (.15)
Age 1.00 (.99, 1.01) –.01* (.003) –.01 (.004)
Male .96 (.36, 2.57) –.08 (.25) .01 (.42)
Race: Non-White (ref: White) .90 (.68, 1.18) –.07 (.06) –.17 (.13)
Unknown .20** (.07, .57) –.06 (.27) –.86* (.39)
Marital status: Unmarried (ref: married) 1.15 (.89, 1.49) .05 (.05) –.17 (.13)
Unknown .64 (.26, 1.56) .15 (.20) –.15 (.32)
Copayment required .90 (.55, 1.48) –.11 (.11) .33 (.37)
Diagnostic Cost Group4 1.22*** (1.17, 1.27) .03** (.01) –.01 (.02)
History of dialysis prior to baseline: 6 months
(ref: none)
.62* (.39, .99) –.15 (.10) –.18 (.14)
1 year .27*** (.16, .47) –.13 (.12) –.15 (.26)
2 years .43*** (.33, .57) .01 (.06) .08 (.11)
History of hospitalization 1-year prior to
baseline
2.13*** (1.65, 2.74) .28*** (.06) .28* (.13)
Distance to nearest VA dialysis, miles .999 (.997, 1.002) –.0005 (.0004) –.0005 (.001)
Region: VISN B (ref: VISN A) 1.59** (1.18, 2.13) .08 (.06) –.14 (.13)
C-statistic 0.79 – –
Notes:
1. * p< .05 **p< .01 ***p<.001.
2. Statistics reported in parens reflect robust 95% Confidence intervals for odds ratio and standard errors for beta coefficients.
3. Total hospitalizations and hospital lengths of stay were modeled with the subset of patients who experienced any hospitalization (n= 655).
4. Results from a restricted model using DCG comorbidity adjustment are shown here. Models that included individual comorbidity indicators yielded similar
results.
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rans’ access to comprehensive, non-dialysis medical care
concurrent with thrice weekly hemodialysis treatment.
The demographic characteristics, mortality rates, and
hospitalization rates in our two region, 2007–2008 co-
hort were similar to characteristics of dialysis patients
from 2001–2003 examined by Hynes and colleagues
(2012). However, the dialysis usage patterns are quite
different across the two studies: Hynes et al. found that
50% of dialysis patients dialyzed in VA (versus 27% in
this study) and 11% received VA-outsourced dialysis
(versus 47% here). These usage differences may be due
to the different sampling approaches, because the Hynes
study prospectively recruited and followed a smaller
sample of patients (n=334) for primary data collection,
whereas here we retrospectively sampled a larger sample
through administrative data. These differences in the
two studies’ geographic sampling and the regional diffe-
rences we found in our own sample suggest variations
that may be due to disease prevalence, local in-house
treatment capacity, or local interpretation and practices
of system-wide level policies. It is imperative to explore
this variation at a larger scale to assist VA ensure dialysis
supply and quality of care for its patients, system-wide.It behooves VA policymakers in the health system to
carefully consider options to address its system of care
for a growing VA patient population with ESRD. Based
on our results, VA’s use of outsourced dialysis in com-
munities may be an appropriate solution that allows VA
to free up limited capacity in existing VA units to treat
acute and sicker chronic patients and minimize patients’
risk for hospitalization. Since VA patients had a nearly
significant, three-fold adjusted risk of death, VA will
need to pay close attention to care coordination and
oversight of veterans receiving outsourced dialysis. Al-
ternatively, if VA-outsourced dialysis veterans are sys-
tematically less complex, then building additional VA
capacity and patient access to more VA-based dialysis
may improve continuity of VA care and reduce VA
expenditures on outsourced dialysis care without com-
promising patient survival outcomes. Another approach
is to formally establish a system of dual-dialysis, where
veterans start dialysis in VA and later transition to VA-
outsourced settings once they are healthy enough for
care in the community. Further research on the impact
of dual use (e.g., sequencing of service settings and care
transitions) on outcomes are needed to inform the
merits of this dual-system approach. Ultimately, the
Table 3 Adjusted all-cause mortality 1-year after baseline
Overall
(n=1,388)
Stratified Sample3
No Hospitalization (n=723) ≥ 1 Hospitalization (n=665)
Dialysis setting: Non-VA (ref: VA) .80 (.48, 1.33) 2.93 (.99, 8.64) .79 (.45, 1.39)
Dual .52* (.31, .86) 1.40 (.40, 4.90) .42** (.24, .74)
Age 1.05*** (1.03, 1.06) 1.05*** (1.03, 1.08) 1.05*** (1.03, 1.07)
Male 2.30 (.29, 18.54)
Race: Non-White (ref: White) .66 (.46, .96)
Unknown .96 (.40, 2.32)
Marital status: Unmarried (ref: married) 1.34 (.95, 1.89)
Unknown 1.22 (.43, 3.43)
Copayment required 1.21 (.65, 2.27)
Diagnostic Cost Group 1.04 (.98, 1.10) 1.03 (.93, 1.15) .99 (.92, 1.06)
History of dialysis prior to baseline:
6 months (ref: none) .84 (.46, 1.55) 1.35 (.53, 3.45) .65 (.28, 1.51)
1 year .61 (.27, 1.39) .69 (.20, 2.38) .76 (.26, 2.23)
2 years .92 (.64, 1.33) 1.03 (.55, 1.90) 1.07 (.65, 1.74)
History of hospitalization 1-year prior to baseline 1.30 (.90, 1.8) 1.01 (.56, 1.84) 1.30 (.82, 2.05)
Distance to nearest VA dialysis, miles 1.001 (.997, 1.004) 1.00 (.99, 1.01) 1.00 (1.00, 1.01)
Region: VISN B (ref: VISN A) .94 (.63, 1.40)
C-statistic 0.70 0.71 0.70
1. Notes: 1. * p< .05 **p< .01 ***p<.001.
2. Adjusted odds ratios reported with robust 95% Confidence intervals noted in parens.
3. Due to the limited distribution of deaths in these stratified samples, explanatory variables in the stratified mortality analyses were restricted to several key
covariates, shown above. Estimates from this restricted model did not differ from estimates from the unrestricted model.
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must be balanced against the tradeoffs of “buying” out-
patient dialysis services from VA-outsourced providers
and potential savings in VA dollars related to other med-
ical care.
The challenges of striking the optimal balance of supply,
access, quality, and costs for dialysis are not unique to the
VA: the development of large integrated health systems
and advent of accountable care organizations (ACOs)
[21,22] emphasize the need to reorganize models of care
delivery to address the same challenges. As the largest
integrated healthcare system in the United States, the VA
is an ACO that is directly responsible for providing com-
prehensive health services, ensuring coordinated and high
quality care among providers that are accountable to each
other, while keeping down costs. In this way, lessons
learned from the VA’s efforts to reorganize life-sustaining
dialysis care, as a component of comprehensive patient
care for those with ESRD, may inform strategies to im-
prove chronic disease care delivery in ACOs and other
health systems.
Limitations
There are a number of study limitations that should be
noted. First, the scope of our analysis was limited to out-
patient dialysis utilization and hospitalizations provided
under financial auspices of the VA because we did nothave access to administrative data on Medicare-funded
services or patients’ other forms of health insurance
coverage at the time of this study. While the VA is the
likely principal source of healthcare for veterans in our
study due to the high frequency of VA copayment ex-
emption (94%) that favors VA- over Medicare-financed
dialysis care (no copayment under VA coverage versus
20% copayment under Medicare), most ESRD veterans
are eligible for Medicare as an alternative to VA cover-
age [3,4,16]. We therefore cannot discount patients’ use of
other medical care in non-VA settings: to the extent that
veterans were hospitalized under Medicare coverage, the
lower hospitalization rate among VA-outsourced patients
may be due to Medicare-covered admissions within the
one-year follow-up period that were not observable in the
VA administrative files.
Second, we were not able to examine intermediate
outcomes of dialysis treatment (e.g., urea reduction ratio,
anemia treatment.), that reflect the quality of dialysis
care across settings and explain differences in outcomes.
Clinical measures like VA laboratory results are available
in veterans’ VA electronic health record, but outsourced
dialysis providers do not report comparable information
on its veteran patients to VA. Third, we were not able to
identify or characterize VA-outsourced dialysis providers
from the VA fee basis claims data. This is important be-
cause the majority of private-sector dialysis facilities are
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between ESRD outcomes and dialysis facility characteris-
tics have excluded VA’s hospital-based facilities [23,24].
Further research is needed to better understand whether
observed differences in veterans’ dialysis outcomes are
attributable to the types of providers VA is outsourcing
its services.
Fourth, our sampling frame included prevalent and inci-
dent ESRD patients for whom we were not able to observe
ESRD vintage (e.g., time since ESRD diagnosis or first dia-
lysis treatment), which may be positively associated with
assigned treatment setting, hospitalization, and mortality.
To minimize the impact of this potential confounder, we
developed a proxy of duration on dialysis (dialysis 0 –
2 years before each subject’s study start date) for adjusted
analyses. Last, we sampled patients from two VA service
regions which illustrated variation in the use of treatment
settings, but constituted a small sample of subjects and
occurrences of outcomes to analyze via unrestricted,
adjusted cause-specific hospitalization and mortality mo-
dels. Despite our efforts to address confounding and selec-
tion biases, these elements of our study design complicate
translation of our results. Thus, our findings should be
interpreted with caution. Future research with a nationally
representative sample of patients’ and their disease and
treatment history will enable survival analysis to assess
outcomes with better precision.
Conclusions
This is the first study to compare hospitalizations and
mortality associated with veterans receiving VA-financed
and coordinated dialysis treatment services in VA, VA-
outsourced, and dual settings. Veterans receiving non-
VA dialysis are systematically less complex, less likely to
be hospitalized, and had shorter lengths-of-stay than
Veterans receiving VA dialysis. For dual dialysis patients,
the likelihood of hospitalization is similar but mortality
is reduced. These findings suggest the need for VA to
consider Veterans’ access to care, long-term savings in
VA expenditures, and optimal patient outcomes in its
strategy for delivering dialysis services. As VA considers
new ways to efficiently and effectively reorganize dialysis
care to address critical shortages in service capacity for a
growing veteran population with ESRD, this study pro-
vides an important step in continued assessment of dia-
lysis outcomes to inform the impact of its make-buy and
care management decisions for dialysis services.
Endnotes
aVeterans may not be able to obtain financial coverage
through both the federal VA healthcare system and Medi-
care programs, simultaneously. VA coverage is variable be-
cause receive a graded amount of benefits based on armed
service-connection status and income. Veterans who havenot previously qualified for Medicare by age or disability
status are eligible for Medicare if they develop renal failure
and have worked the required amount of time to be
eligible for Social Security benefits, but must wait 90-days
to enroll in the Medicare ESRD program and another
33-months for Medicare to serve as the primary payor for
healthcare services.
bPatient cost-sharing is $0 or $15 per treatment session
for veterans financing care through VA versus Part B pre-
miums and 20% copayment of charges (approximately $30
per treatment) under Medicare.
Abbreviations
ACO: Accountable Care Organization; DCG: Diagnostic Cost Group; ESRD: End
Stage Renal Disease; FB: Fee Basis; PTF: Patient Treatment File; VA: Veterans
Health Administration; VAMC: Veterans Affairs Medical Center; VISN: Veterans
Integrated Service Network.Competing interests
Dr. Maciejewski reports serving as consultant for Takeda Pharmaceuticals,
Novartis, and the Surgical Review Corporation and owning stock in Amgen;
his spouse is employed by Amgen. Dr. Patel has received consultation funds
from Kai Pharmaceuticals, Abbott Laboratories, and received research
funding from Amgen, Eli Lilly & Co., and Daiichi Sankyo for clinical trial event
adjudication activities. The other authors (VW, DMH, KMS, MW) report no
relationship or financial interest with any entity that would pose a conflict of
interest to the subject matter of this article. The views expressed in this
article are those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs, Duke University, University of
Chicago, or the University of North Carolina at Chapel Hill. An earlier version
of this manuscript was presented at the 2012 AcademyHealth and American
Society of Nephrology Annual Research Meetings.Authors’ contributions
VW conceived and obtained funding of this study, led its design and
statistical analysis, coordinated and drafted the manuscript. MLM, MW, and
UDP participated in the study design, analysis and interpretation of data, and
critical revision of the manuscript. DMH participated in the acquisition and
analysis of data and provided critical revision of the manuscript. KMS
performed data programming, conducted statistical analysis and drafted the
manuscript. All authors read and approved the final manuscript.Acknowledgements
The authors thank Drs. Kevin Stroupe and Margaret Browning for sharing
their methodological expertise and Ms. Lynn Van Scoyoc for excellent data
programming. This work was supported by the Department of Veterans
Affairs Office of Research and Development Project PPO-09-312 (VW), the
Agency for Healthcare Research and Quality K12 HS019479 (VW), and the
Department of Veterans Affairs Research Career Scientist Awards RCS-10-391
(MLM) and RCS-91-408 (MW).
Author details
1Health Services Research and Development, Durham VA Medical Center,
Durham, NC 27705, USA. 2Division of General Internal Medicine, Department
of Medicine, Duke University, Durham, NC 27705, USA. 3Division of
Nephrology, Department of Medicine, Duke University, Durham, NC 27705,
USA. 4VA Information Resource Center, Hines VA Hospital, Riverside, IL 60546,
USA. 5Center for Management of Complex Chronic Care, Hines VA Hospital,
Riverside, IL 60546, USA. 6Department of Medicine, University of Illinois-
Chicago College of Medicine, Chicago, IL 60612, USA. 7Department of Health
Policy and Management, School of Public Health, University of North
Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Received: 15 August 2012 Accepted: 10 January 2013
Published: 18 January 2013
Wang et al. BMC Health Services Research 2013, 13:26 Page 9 of 9
http://www.biomedcentral.com/1472-6963/13/26References
1. US Renal Data System: USRDS 2012 Annual Data Report: Atlas of End-Stage
Renal Disease in the United States. Bethesda, MD: National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases;
2012.
2. Allocation Resource Center: Annual Workload and Cost Report (FY2011);
[http://vaww.arc.med.va.gov/vpublic/arci_sr4v3.asp?sDTP=11&sSO=2011FY]
3. Hynes DM, Cowper DC, Manheim L, Sohn MW, Stroupe K, Weaver FM,
Freedman J: Research findings from the VA Medicare data merge initiative:
Veterans’ enrollment, access, and use of Medicare and VA Health Services (XVA
69–001). Report to the Under Secretary for Health, Department of Veteran
Affairs. Hines, IL: VA Information Resource Center, Health Services Research
and Development Service; 2003.
4. Hynes DM, Stroupe KT, Fischer MJ, Reda DJ, Manning W, Browning MM,
Huo Z, Saban K, Kaufman JS: Comparing VA and private sector healthcare
costs for end-stage renal disease. Medical care 2012, 50(2):161–170.
5. Veterans Health Administration Chief Business Office: Purchase of Non-VA
Hemodialysis Treatments 2009. Department of Veterans Affairs.
6. Stroupe KT, Fischer MJ, Kaufman JS, O’Hare AM, Sohn MW, Browning MM,
Huo Z, Hynes DM: Predialysis nephrology care and costs in elderly
patients initiating dialysis. Medical care 2011, 49(3):248–256.
7. VHA Costs in Cost Distribution Report, FY1993-FY2003; [http://vaww.herc.
research.va.gov/files/MXLS_370.xls]
8. Workload report: Non-VA care dialysis CPTs by disbursed amount, FY2011;
[http://reports2.vssc.med.va.gov/ReportServer/Pages/ReportViewer.aspx?%
2fNVA%2frptMgmt%2Non+VA+Care+Dialysis+CPTs+by+Disbursed
+Amount3&rs:Command=Render]
9. Trivedi AN, Matula S, Miake-Lye I, Glassman PA, Shekelle P, Asch S:
Systematic review: comparison of the quality of medical care in Veterans
Affairs and non-Veterans Affairs settings. Medical care 2011, 49(1):76–88.
10. Fischer MJ, Stroupe KT, Kaufman JS, O’Hare AM, Browning MM, Huo Z,
Hynes DM: Predialysis nephrology care among older veterans using
Department of Veterans Affairs or Medicare-covered services.
Am J Manag Care 2010, 16(2):e57–66.
11. Hurst FP, Abbott KC, Raj D, Krishnan M, Palant CE, Agodoa LY, Jindal RM:
Arteriovenous fistulas among incident hemodialysis patients in
Department of Defense and Veterans Affairs facilities. J Am Soc Nephrol
2010, 21(9):1571–1577.
12. Parikh DS, Inrig JK, Kipp A, Szczech LA, McClellan W, Patel UD: Veterans
more likely to start hemodialysis with an arteriovenous fistula. Semin Dial
2011, 24(5):570–575.
13. Gill JS, Hussain S, Rose C, Hariharan S, Tonelli M: Access to kidney
transplantation among patients insured by the United States
Department of Veterans Affairs. J Am Soc Nephrol 2007, 18(9):2592–2599.
14. Wolinsky FD, An H, Liu L, Miller TR, Rosenthal GE: Exploring the association
of dual use of the VHA and Medicare with mortality: separating the
contributions of inpatient and outpatient services. BMC Health Serv Res
2007, 7:70.
15. Wolinsky FD, Miller TR, An H, Brezinski PR, Vaughn TE, Rosenthal GE: Dual
use of Medicare and the Veterans Health Administration: are there
adverse health outcomes? BMC Health Serv Res 2006, 6:131.
16. US Renal Data System: USRDS 2009 Annual Data Report: Atlas of End-Stage
Renal Disease in the United States. Bethesda, MD: National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases;
2009.
17. Data Quality Alert (June 2007) in Medical SAS Datasets; http://vaww.virec.
research.va.gov/DataSourcesCategory/DataQuality/HSRD_Data_Quality_Alert.
pdf.
18. Fan VS, Maciejewski ML, Liu CF, McDonnell M, Fihn SD: Comparison of risk
adjustment measures based on self-report, administrative data, and
pharmacy records to predict clinical outcomes. Health Serv Outcomes Res
Methodol 2006, 6(1–2):21–36.
19. Maciejewski ML, Liu CF, Derleth A, McDonell M, Anderson S, Fihn SD: The
performance of administrative and self-reported measures for risk
adjustment of Veterans Affairs expenditures. Health Serv Res 2005,
40(3):887–904.
20. Maciejewski ML, Liu CF, Fihn SD: Performance of comorbidity, risk
adjustment, and functional status measures in expenditure prediction
for patients with diabetes. Diabetes Care 2009, 32(1):75–80.21. Burns LR, Pauly MV: Accountable care organizations may have difficulty
avoiding the failures of integrated delivery networks of the 1990s.
Health affairs (Project Hope) 2012, 31(11):2407–2416.
22. Fisher ES, Shortell SM, Kreindler SA, Van Citters AD, Larson BK: A framework
for evaluating the formation, implementation, and performance of
accountable care organizations. Health affairs (Project Hope) 2012,
31(11):2368–2378.
23. Garg PP, Frick KD, Diener-West M, Powe NR: Effect of the ownership of
dialysis facilities on patients’ survival and referral for transplantation.
N Engl J Med 1999, 341(22):1653–1660.
24. Hirth RA, Held PJ, Orzol SM, Dor A: Practice patterns, case mix, Medicare
payment policy, and dialysis facility costs. Health Serv Res 1999,
33(6):1567–1592.
doi:10.1186/1472-6963-13-26
Cite this article as: Wang et al.: Comparison of outcomes for veterans
receiving dialysis care from VA and non-VA providers. BMC Health
Services Research 2013 13:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
